

Automated real-time nucleic acid
amplification technology for rapid
and simultaneous detection of tuberculosis
and rifampicin resistance:

Xpert MTB/RIF assay for the diagnosis
of pulmonary and extrapulmonary TB
in adults and children

NEW DIAGNOSTIC TESTS
POLICY UPDATE
TUBERCULOSIS
DIAGNOSIS
RESISTANCE
PULMONARY TB
RIFAMPICIN
TB
DRUG-RESISTANCE
TB/HIV
PERFORMANCE
ACCURACY
RECOMMENDATIONS
MYCOBACTERIUM
MOLECULAR DIAGNOSTICS
RAPID TB TEST



World Health
Organization

Automated real-time nucleic acid amplification
technology for rapid and simultaneous detection
of tuberculosis and rifampicin resistance:
Xpert MTB/RIF assay for the diagnosis
of pulmonary and extrapulmonary TB
in adults and children

Policy update



World Health
Organization

WHO Library Cataloguing-in-Publication Data

Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extra-pulmonary TB in adults and children. Policy update.

Revision of Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Policy statement. Geneva, World Health Organization, 2011.

1.Tuberculosis, Multidrug-resistant - diagnosis. 2.Tuberculosis - diagnosis. 3.Rifampin - pharmacology. 4.Mycobacterium tuberculosis - isolation and purification. 5.HIV infections - diagnosis. 6.Sensitivity and specificity. 7.Guideline. I. World Health Organization.

ISBN: 978 92 4 150633 5

(NLM classification: WF 310)

© World Health Organization 2013

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Designed by GPS Publishing

Printed in France

WHO/HTM/TB/2013.16

Contents

EXECUTIVE SUMMARY	XI
WHO'S POLICY RECOMMENDATIONS	XV
1. BACKGROUND	1
2. METHODS	3
2.1 EVIDENCE SYNTHESIS	3
2.2 EXPERT GROUP MEETING	7
2.3 EXTERNAL REVIEW	7
2.4 PREPARING THE POLICY UPDATE	7
3. SCOPE	8
3.1 DATE OF REVIEW: 2017	8
4. EVIDENCE BASE FOR POLICY FORMULATION	9
4.1 USING XPERT MTB/RIF TO DIAGNOSE PULMONARY TB AND RIFAMPICIN RESISTANCE IN ADULTS	9
4.1.1 USING XPERT MTB/RIF AS A REPLACEMENT TEST FOR SMEAR MICROSCOPY	10
4.1.2 USING XPERT MTB/RIF AS AN ADD-ON TEST FOLLOWING MICROSCOPY	12
4.1.3 USING XPERT MTB/RIF TO DETECT SMEAR-POSITIVE CULTURE-POSITIVE TB	12
4.1.4 USING XPERT MTB/RIF TO DETECT SMEAR-NEGATIVE CULTURE-POSITIVE TB	12
4.1.5 USING XPERT MTB/RIF TO DETECT PULMONARY TB IN HIV-NEGATIVE AND HIV- POSITIVE INDIVIDUALS	12
4.1.6 USING XPERT MTB/RIF TO DETECT RIFAMPICIN RESISTANCE	14
4.1.7 EFFECT OF THE VERSION OF THE XPERT MTB/RIF ASSAY	15
4.1.8 ACCURACY OF THE XPERT MTB/RIF G4 CARTRIDGE	15
4.1.9 ACCURACY OF THE REFERENCE STANDARDS	16
4.2 USING XPERT MTB/RIF TO DIAGNOSE EXTRAPULMONARY TB AND RIFAMPICIN RESISTANCE IN ADULTS AND CHILDREN	17
4.2.1 DETECTING LYMPH NODE TB IN SAMPLES FROM BIOPSY OR FINE-NEEDLE ASPIRATION	18
4.2.2 DETECTING PLEURAL TB IN PLEURAL FLUID	19
4.2.3 DETECTING TB IN SAMPLES OF CSF	20
4.2.4 DETECTING TB IN GASTRIC FLUID	22
4.2.5 DETECTING TB IN TISSUE SAMPLES	22
4.2.6 DETECTING RIFAMPICIN RESISTANCE	23

4.3 USING XPERT MTB/RIF TO DIAGNOSE TB AND RIFAMPICIN RESISTANCE IN CHILDREN	23
4.3.1 USING XPERT MTB/RIF TO DIAGNOSE PULMONARY TB IN CHILDREN	24
4.3.2 XPERT MTB/RIF COMPARED WITH SMEAR MICROSCOPY	26
4.3.3 PERFORMANCE OF XPERT MTB/RIF IN SMEAR-POSITIVE AND SMEAR-NEGATIVE CHILDREN	27
4.3.4 XPERT MTB/RIF IN CHILDREN AGED 0–4 YEARS AND 5–15 YEARS	29
4.3.5 XPERT MTB/RIF IN HIV-POSITIVE AND HIV-NEGATIVE CHILDREN	30
4.3.6 USING XPERT MTB/RIF TO DETECT PERIPHERAL LYMPH NODE TB IN CHILDREN	32
4.3.7 USING XPERT MTB/RIF TO DETECT TB MENINGITIS IN CHILDREN	32
4.3.8 USING XPERT MTB/RIF TO DETECT RIFAMPICIN RESISTANCE IN CHILDREN	32
4.4 AFFORDABILITY AND COST EFFECTIVENESS OF USING XPERT MTB/RIF TO DIAGNOSE TB	33
5. WHO'S POLICY RECOMMENDATIONS	38
5.1 USING XPERT MTB/RIF TO DIAGNOSE PULMONARY TB AND RIFAMPICIN RESISTANCE IN ADULTS AND CHILDREN	38
5.2 USING XPERT MTB/RIF TO DIAGNOSE EXTRAPULMONARY TB AND RIFAMPICIN RESISTANCE IN ADULTS AND CHILDREN	39
6. IMPLEMENTATION CONSIDERATIONS	39
6.1 RESEARCH NEEDS	42
6.2 PLANS FOR SUPPORTING SCALE-UP OF THE IMPLEMENTATION OF XPERT MTB/RIF	42
7. GRADE TABLES	44
ANNEXES	74
ANNEX 1. MEMBERS OF THE EXPERT GROUP	74
ANNEX 2. WHO STAFF MEMBERS	76
ANNEX 3. MEMBERS OF THE STRATEGIC AND TECHNICAL ADVISORY GROUP FOR TUBERCULOSIS (STAG-TB)	76
ANNEX 4. DECLARATIONS OF INTERESTS	78

Tables

TABLE 1.	META-ANALYSIS OF THE SENSITIVITY AND SPECIFICITY OF XPERT MTB/RIF IN DIAGNOSING EXTRAPULMONARY TB AND RIFAMPICIN RESISTANCE IN ADULTS AND CHILDREN COMPARED AGAINST CULTURE AS A REFERENCE STANDARD AS WELL AS AGAINST A COMPOSITE REFERENCE STANDARD, BY TYPE OF EXTRAPULMONARY SPECIMEN	xiii
TABLE 2.	POOLED SENSITIVITY AND SPECIFICITY OF THE XPERT MTB/RIF ASSAY FOR DETECTING PULMONARY TB AND RIFAMPICIN RESISTANCE	12
TABLE 3.	META-ANALYSIS OF THE ESTIMATED SENSITIVITY AND SPECIFICITY OF SMEAR MICROSCOPY IN DIAGNOSING PULMONARY TB, PERIPHERAL LYMPH NODE TB AND TB MENINGITIS IN CHILDREN COMPARED AGAINST CULTURE AS A REFERENCE STANDARD IN PUBLISHED AND UNPUBLISHED STUDIES	27
TABLE 4.	META-ANALYSIS OF THE SENSITIVITY AND SPECIFICITY OF XPERT MTB/RIF IN DIAGNOSING PULMONARY TB, PERIPHERAL LYMPH NODE TB AND TB MENINGITIS COMPARED AGAINST CULTURE AS A REFERENCE STANDARD IN SMEAR-NEGATIVE AND SMEAR-POSITIVE CHILDREN IN PUBLISHED AND UNPUBLISHED STUDIES	29
TABLE 5.	META-ANALYSIS COMPARING XPERT MTB/RIF FOR DIAGNOSING PULMONARY TB, PERIPHERAL LYMPH NODE TB AND TB MENINGITIS USING CULTURE AS A REFERENCE STANDARD IN HIV-POSITIVE AND HIV-NEGATIVE CHILDREN, STRATIFIED BY SMEAR STATUS	31
TABLE 6.	METAREGRESSION MODEL FOR XPERT MTB/RIF USING SAMPLES OF EXPECTORATED OR INDUCED SPUTUM FROM CHILDREN, CONTROLLING FOR SMEAR STATUS AND HIV STATUS	31
TABLE 7.	OVERVIEW OF STUDIES COMPARING THE COSTS OF USING XPERT MTB/RIF AND FOLLOW-ON TESTS WITH CURRENT DIAGNOSTIC ALGORITHMS FOR DIAGNOSING TB AND MDR-TB	34
TABLE 8.	GRADE EVIDENCE PROFILE: ACCURACY OF XPERT MTB/RIF IN DIAGNOSING PULMONARY TB IN ADULTS	44
TABLE 9.	GRADE EVIDENCE PROFILE: ACCURACY OF XPERT MTB/RIF IN DIAGNOSING PULMONARY TB IN SPUTUM SMEAR-POSITIVE ADULTS	45
TABLE 10.	GRADE EVIDENCE PROFILE: ACCURACY OF XPERT MTB/RIF IN DIAGNOSING PULMONARY TB IN SPUTUM SMEAR-NEGATIVE ADULTS	46
TABLE 11.	GRADE EVIDENCE PROFILE: ACCURACY OF XPERT MTB/RIF IN DIAGNOSING PULMONARY TB IN ADULTS LIVING WITH HIV	47
TABLE 12.	GRADE EVIDENCE PROFILE: ACCURACY OF XPERT MTB/RIF IN DIAGNOSING PULMONARY TB IN ADULTS WITHOUT HIV INFECTION	48
TABLE 13.	GRADE EVIDENCE PROFILE: THE INCREMENTAL YIELD OF XPERT MTB/RIF COMPARED WITH MICROSCOPY IN PATIENTS WITH CULTURE-CONFIRMED TB	49
TABLE 14.	GRADE EVIDENCE PROFILE: ACCURACY OF XPERT MTB/RIF IN DIAGNOSING PULMONARY TB IN ADULTS AS AN ADD-ON TEST FOLLOWING NEGATIVE SPUTUM-SMEAR MICROSCOPY	50
TABLE 15.	SENSITIVITY OF XPERT MTB/RIF IN SMEAR-NEGATIVE CULTURE-CONFIRMED PULMONARY TB IN INDIVIDUALS, BY HIV STATUS	51

TABLE 16.	GRADE EVIDENCE PROFILE: ADDITIONAL YIELD OF XPERT MTB/RIF OVER MICROSCOPY IN SMEAR-NEGATIVE TB	51
TABLE 17.	GRADE EVIDENCE PROFILE: ACCURACY OF XPERT MTB/RIF IN DETECTING RIFAMPICIN RESISTANCE, WHERE XPERT MTB/RIF REPLACES PHENOTYPIC CULTURE-BASED DRUG-SUSCEPTIBILITY TESTING AS THE INITIAL TEST	52
TABLE 18.	ACCURACY OF XPERT MTB/RIF IN DETECTING TB IN LYMPH NODE FLUID AND TISSUE (A. EVIDENCE PROFILE, B. SUMMARY OF FINDINGS)	53
TABLE 19.	ACCURACY OF XPERT MTB/RIF IN DETECTING TB IN PLEURAL FLUID (A. EVIDENCE PROFILE, B. SUMMARY OF FINDINGS)	55
TABLE 20.	ACCURACY OF XPERT MTB/RIF IN DETECTING TB IN CEREBROSPINAL FLUID (A. EVIDENCE PROFILE, B. SUMMARY OF FINDINGS)	57
TABLE 21.	GRADE EVIDENCE PROFILE: ACCURACY OF XPERT MTB/RIF IN DETECTING TB IN GASTRIC FLUID	59
TABLE 22.	GRADE EVIDENCE PROFILE: ACCURACY OF XPERT MTB/RIF IN DETECTING TB IN TISSUE SAMPLES	60
TABLE 23.	GRADE EVIDENCE PROFILE: ACCURACY OF XPERT MTB/RIF IN DETECTING RIFAMPICIN RESISTANCE IN NONRESPIRATORY SPECIMENS	61
TABLE 24.	GRADE EVIDENCE PROFILE: ACCURACY OF XPERT MTB/RIF IN DETECTING TB IN CHILDREN COMPARED WITH CULTURE AS A REFERENCE STANDARD (A. EXPECTORATED SPUTUM AND INDUCED SPUTUM, B. GASTRIC LAVAGE OR ASPIRATE, C. SUMMARY OF FINDINGS)	62
TABLE 25.	GRADE EVIDENCE PROFILE: ACCURACY OF XPERT MTB/RIF IN DETECTING TB IN CHILDREN COMPARED WITH A CLINICAL REFERENCE STANDARD (A. EXPECTORATED SPUTUM AND INDUCED SPUTUM, AND GASTRIC LAVAGE AND ASPIRATE, B. SUMMARY OF FINDINGS)	63
TABLE 26.	GRADE EVIDENCE PROFILE: ACCURACY OF XPERT MTB/RIF IN DETECTING TB IN CHILDREN FOLLOWING NEGATIVE SMEAR MICROSCOPY (A. EVIDENCE PROFILE, B. SUMMARY OF FINDINGS, C. ADDITIONAL YIELD OF XPERT MTB/RIF OVER MICROSCOPY)	64
TABLE 27.	INCREMENTAL YIELD OF XPERT MTB/RIF COMPARED WITH SMEAR MICROSCOPY IN CHILDREN WITH CULTURE-CONFIRMED TB (A. EXPECTORATED SPUTUM AND INDUCED SPUTUM, B. GASTRIC LAVAGE OR ASPIRATE)	70
TABLE 28.	GRADE EVIDENCE PROFILE: ACCURACY OF XPERT MTB/RIF IN DETECTING RIFAMPICIN RESISTANCE IN RESPIRATORY SPECIMENS FROM CHILDREN	71
TABLE 29.	GRADE EVIDENCE PROFILE: ACCURACY OF XPERT MTB/RIF IN DETECTING PERIPHERAL LYMPH NODE TB IN CHILDREN	72
TABLE 30.	GRADE EVIDENCE PROFILE AND SUMMARY OF FINDINGS: ACCURACY OF XPERT MTB/RIF IN DETECTING TB MENINGITIS IN CHILDREN	73

Figures

FIGURE 1.	STEPS IN USING THE XPERT MTB/RIF ASSAY	2
FIGURE 2.	SELECTION OF STUDIES EVALUATING THE ACCURACY OF XPERT MTB/RIF IN DIAGNOSING PULMONARY TB AND RIFAMPICIN RESISTANCE IN ADULTS: FLOW DIAGRAM OF STUDIES IDENTIFIED BY THE INITIAL LITERATURE SEARCHES	9
FIGURE 3.	SELECTION OF STUDIES EVALUATING THE ACCURACY OF XPERT MTB/RIF IN DIAGNOSING PULMONARY TB AND RIFAMPICIN RESISTANCE IN ADULTS: FLOW DIAGRAM OF STUDIES IDENTIFIED BY THE UPDATED LITERATURE SEARCH	10
FIGURE 4.	FOREST PLOT OF THE SENSITIVITY AND SPECIFICITY OF XPERT MTB/RIF FOR DETECTING PULMONARY TB IN 27 STUDIES (36 STUDY CENTRES)	11
FIGURE 5.	FOREST PLOTS OF THE SENSITIVITY AND SPECIFICITY OF XPERT MTB/RIF FOR DETECTING PULMONARY TB IN HIV-NEGATIVE INDIVIDUALS SUSPECTED OF HAVING TB (9 STUDIES, 18 STUDY CENTRES) AND HIV-POSITIVE INDIVIDUALS SUSPECTED OF HAVING TB (10 STUDIES, 16 CENTRES)	13
FIGURE 6.	FOREST PLOTS OF THE SENSITIVITY AND SPECIFICITY OF XPERT MTB/RIF FOR DETECTING RIFAMPICIN RESISTANCE WHEN XPERT MTB/RIF WAS USED AS AN INITIAL TEST REPLACING PHENOTYPIC CULTURE-BASED DRUG-SUSCEPTIBILITY TESTING IN 24 STUDIES (33 STUDY CENTRES). (STUDIES ARE PRESENTED IN ORDER OF DECREASING SENSITIVITY AND DECREASING NUMBER OF TRUE-POSITIVE RESULTS)	14
FIGURE 7.	SELECTION OF STUDIES EVALUATING THE ACCURACY OF XPERT MTB/RIF IN DIAGNOSING EXTRAPULMONARY TB AND DETECTING RIFAMPICIN RESISTANCE IN ADULTS AND CHILDREN: FLOW DIAGRAM OF STUDIES INCLUDED IN THE REVIEW	17
FIGURE 8.	FOREST PLOT OF THE SENSITIVITY AND SPECIFICITY OF XPERT MTB/RIF IN DETECTING EXTRAPULMONARY TB IN LYMPH NODE SAMPLES (TISSUE OR ASPIRATE) COMPARED WITH CULTURE AS THE REFERENCE STANDARD	18
FIGURE 9.	FOREST PLOT OF THE SENSITIVITY AND SPECIFICITY OF XPERT MTB/RIF IN DETECTING EXTRAPULMONARY TB IN LYMPH NODE SAMPLES (TISSUE OR ASPIRATE) COMPARED WITH A COMPOSITE REFERENCE	

预览已结束，完整报告链

<https://www.yunbaogao.cn/report/index/r>